Setipiprant, KYTH-105
CAS 866460-33-5
2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid
2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid
5H-Pyrido(4,3-b)indole-5-acetic acid, 8-fluoro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-
MF C24H19FN2O3MW 402.4176632
IND FILED BY ALLERGAN FOR Alopecia
ACT-129968, a CRTH2 receptor antagonist, had been in phase II clinical trials at Actelion
Setipiprant; UNII-BHF20LA2GM; ACT-129968; 866460-33-5;
Setipiprant is a prostaglandin D2 (PGD2) antagonist. Essentially, it inhibits PGD2 receptor activity
KYTH-105 had previously been studied as a potential allergic inflammation treatment and had undergone eight clinical trials, resulting in a safety database of more than 1,000 patients. Treatment in all studies was well tolerated across all treatment groups.
Intellectual Property
KYTHERA acquired exclusive worldwide rights to KYTH-105, as well as certain patent rights covering the use of PGD2 receptor antagonists for the treatment of hair loss (often presenting as male pattern baldness, or androgenic alopecia).
Next Steps
KYTHERA plans to file an Investigational New Drug (IND) application and initiate a proof-of-concept study to establish the efficacy of KYTH-105 in male subjects with androgenic alopecia (AGA).
In 2015, Allergan acquired Kythera.
2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid
mp 224.0 °C.
LC(1)/ESI-MS tR = 0.83 min; m/z [M + H+] = 403.09.
1H NMR (DMSO-d6), 65:35 mixture of two rotamers, δ: 8.02 (m, 2 H), 7.76 (d, J = 7.8 Hz, 0.65 H), 7.72 (m, 0.35 H), 7.49–7.64 (m, 3.35 H), 7.35–7.49 (m, 2.35 H), 6.98 (ddd, JH–F = 9.3 Hz, J1 = 9.3 Hz, J2 = 2.4 Hz, 0.65 H), 6.88 (m, 0.65 H), 4.85–5.14 (m, 3.3 H), 4.42 (m, 0.35 H), 4.32 (m, 0.7 H), 4.06 (m, 0.35 H), 3.50 (t, J = 5.5 Hz, 1.3 H), 2.95 (m, 0.70 H), 2.68 (m, 0.65 H), 2.58 (m, 0.65 H).
13C NMR (DMSO-d6) δ: 170.7, 169.2, 157.7 (d, JC–F = 232 Hz), 157.4 (d, JC–F = 233 Hz), 137.1, 136.2, 135.1, 134.9, 134.0, 133.8, 133.5, 129.6, 129.5, 129.4, 129.3, 128.9, 128.8, 127.5, 127.4, 127.0, 126.9, 126.0, 125.9, 125.7 (d, JC–F = 10 Hz), 125.2, 125.1, 125.0, 124.1, 123.9, 110.9 (d, JC–F = 10 Hz), 110.8 (m), 109.3 (d, JC–F = 26 Hz), 109.1 (d, JC–F = 26 Hz), 106.7 (m), 103.3 (d, JC–F = 23 Hz), 103.0 (d, JC–F = 23 Hz), 44.73, 44.70, 44.5, 44.4, 39.5, 39.3, 23.1, 22.3.
HRMS (ESI): m/zcalcd for C24H20N2O3F [M + H+] 403.1458, found 403.1458.
SYNTHERSIS
Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2).[1] It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients,[2][3] it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.[4]
However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness,[5] the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action.[6] While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly.[7]
Prostaglandin D2 is a known agonist of the thromboxane A2 (TxA2) receptor, the PGD2 (DP) receptor and the recently identified G-protein-coupled “chemoattractant receptor- homologous molecule expressed on Th2 cells” (CRTH2).
The response to allergen exposure in a previously sensitized host results in a cascade effect involving numerous cell types and release of a number of cytokines, chemokines, and multiple mediators. Among these critical initiators are the cytokines interleukin (IL)-4, IL-13, and IL-5, which play critical roles in Th2 cell differentiation, immunoglobulin (Ig)E synthesis, mast cell growth and differentiation, upregulation of CD23 expression, and the differentiation, recruitment, and activation of eosinophils. The stimulated release of the array of mediators, causes end-organ damage, including constriction and hyperresponsi- veness, vascular permeability, edema, mucous secretion, and further inflammation.
Because of the number of responses targeted, corticosteroids have proven to be the most effective therapy. Rather than antagonizing these specific responses in a directed way, another approach is to alter the immune response, that is, to change the nature of the immunological response to allergen. CRTH2 is preferentially expressed on Th2 cells and is a chemoattractant receptor for PGD2 that mediates PGD2-dependent migration of blood Th2 cells. Chemoattractants are responsible for the recruitment of both Th2 cells and other effector cells of allergic inflammation, which can provide the conceptual basis for the development of new therapeutic strategies in allergic conditions.
So far, few compounds having CRTH2 antagonistic activity have been reported in the patent literature. Bayer AG claims the use of Ramatroban ((3R)-3-(4-fluorobenzene- sulfonamido)-l,2,3,4-tetrahydrocarbazole-9-propionic acid) for the prophylaxis and treatment of allergic diseases, such as asthma, allergic rhinitis or allergic conjuvatitis
(GB 2388540). Further, (2-tert.-butoxycarbonyl-l, 2, 3, 4-tetrahydro-pyrido[4,3-b]indol-5- yl)-acetic acid and (2-ethoxycarbonyl-l, 2, 3, 4-tetrahydro-pyrido[4,3-b]indol~5-yl)-acetic acid are disclosed by Kyle F. et al in two patent applications (US 5817756 and WO 9507294, respectively).
Furthermore, oral bioavailability of the Ramatroban and its ability to inhibit prostaglandin D2-induced eosinophil migration in vitro has been reported (Journal of Pharmacology and Experimental Therapeutics, 305(1), p.347-352 (2003)).
Description of the invention:
It has now been found that compounds of the general Formulae (I) and (II) of the present invention are CRTH2 receptor antagonists. These compounds are useful for the treatment of both chronic and acute allergic/immune disorders such as allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis, basophil- related diseases, such as basophilic leukemia and basophilic leukocytosis.
The compounds of general Formulae (I) and (II), especially those mentioned as being preferred, display high selectivity towards the CRTH2 receptor. No antagonistic effects (IC50 >10 μM) are observed on e.g. prostaglandin D2 receptor DPI; PGI2 receptor (IP), PGE2 receptors (EPl, EP2, EP3, EP4), PGF2 receptor (FP), thromboxane receptor A2 (TxA2), leukotriene receptors (CysLTl, CysLT2, LTB4), complement receptor (C5a), angiotensin receptors (ATI, AT2) or serotonin receptor 5HT2c.
The solubility of compounds of general Formulae (I) and (II) in buffer at pH 7 is generally >800 μg/ml.
In vitro assays with rat and dog liver microsomes, or with rat and human hepatocytes revealed high metabolic stability for compounds of general Foπnulae (I) and (II), especially for those compounds mentioned as being preferred.
The compounds of general Formulae (I) and (II), especially those mentioned as being preferred, do not interfere with cytochrome P-450 enzymes, e.g. they are neither degraded by, nor do they inhibit such enzymes.
Excellent pharmacokinetic profiles have been observed for compounds of general Formulae (I) and (II), especially for those compounds mentioned as being preferred, after oral administration (10 mg/kg) to rats and dogs (bioavailability 20-80%, Tmax 30 min, Cmax 2000- 6000 ng/ml, low clearance, T] 24-8 h). The compounds of general Formulae (I) and (II), especially those mentioned as being preferred, are efficacious in vitro, inhibiting PGD2-induced migration of eosinophils or other CRTH2 expressing cells in a cell migration assay. A number of techniques have been developed to assay such chemotactic migration (see, e.g., Leonard et al., 1995, “Measurement of α- and β-Chemokines”, in Current Protocols in Immunology, 6.12.1- 6.12.28, Ed. Coligan et al, John Wiley & Sons, Inc. 1995). The compounds of the present invention are tested using a protocol according to H. Sugimoto et al. (J Pharmacol Exp Ther. 2003, 305(1), 347-52), or as described hereinafter: Purified eosinophils are labeled with a fluorescent dye, i.e. Calcein-AM and loaded in BD Falcon FluoroBlock upper inserts. Test compounds are diluted and incubated with eosinophils in the BD Falcon
FluoroBlock upper inserts for 30 min at 37 °C in a humidified CO2 incubator. A constant amount of PGD2 is added to BD Falcon FluoroBlock lower chamber, at a concentration known to have a chemotactic effect on CRTH2 cells. As a control, at least one aliquot in the upper well does not contain test compound. The inserts are combined with the chambers and are incubated for 30 min at 37 °C in a humidified CO2 incubator. After an incubation period, the number of migrating cells on the lower chamber is counted using a fluorescent reader, i.e. an Applied Biosystems Cyto Fluor 4000 plate reader. The contribution of a test compound to the chemotactic activity of PGD2 is measured by comparing the chemotactic activity of the aliquots containing only dilution buffer with the activity of aliquots containing a test compound. If addition of the test compound to the solution results in a decrease in the number of cells detected in the lower chamber relative to the number of cells detected using a solution containing only PGD2, then there is identified an antagonist of PGD2 induction of chemotactic activity of eosinophils.
PAPER
Journal of Medicinal Chemistry (2013), 56(12), 4899-4911
http://pubs.acs.org/doi/abs/10.1021/jm400122f
Identification of 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonist
Drug Discovery Unit, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
J. Med. Chem., 2013, 56 (12), pp 4899–4911
DOI: 10.1021/jm400122f
Herein we describe the discovery of the novel CRTh2 antagonist 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid 28
(setipiprant/ACT-129968), a clinical development candidate for the
treatment of asthma and seasonal allergic rhinitis. A lead optimization
program was started based on the discovery of the recently disclosed
CRTh2 antagonist 2-(2-benzoyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid 5. An already favorable and druglike profile could be assessed for lead compound 5.
Therefore, the lead optimization program mainly focused on the
improvement in potency and oral bioavailability. Data of newly
synthesized analogs were collected from in vitro pharmacological,
physicochemical, in vitro ADME, and in vivo pharmacokinetic studies in
the rat and the dog. The data were then analyzed using a traffic light
selection tool as a visualization device in order to evaluate and
prioritize candidates displaying a balanced overall profile. This
data-driven process and the excellent results of the PK study in the rat
(F = 44%) and the dog (F = 55%) facilitated the identification of 28 as a potent (IC50 = 6 nM), selective, and orally available CRTh2 antagonist.
PAtentWO 2005095397
http://www.google.co.in/patents/WO2005095397A1?cl=en
Formula 6.
Step a)
Formula (I).
References
- Fretz H, Valdenaire A, Pothier J, Hilpert K, Gnerre C, Peter O, Leroy X, Riederer MA. Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist. J Med Chem. 2013 Jun 27;56(12):4899-911. doi: 10.1021/jm400122f PMID 23721423
- Sidharta PN, Diamant Z, Dingemanse J. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects. Fundam Clin Pharmacol. 2014 Dec;28(6):690-9. doi: 10.1111/fcp.12079 PMID 24734908
- Diamant Z, Sidharta PN, Singh D, O’Connor BJ, Zuiker R, Leaker BR, Silkey M, Dingemanse J. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52. doi: 10.1111/cea.12357 PMID 24964348
- Norman P. Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66. doi: 10.1517/13543784.2013.839658 PMID 24073896
- Garza LA, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Science Translational Medicine, 21 March 2012; 4(126):126ra34. doi: 10.1126/scitranslmed.3003122
- George Cotsarelis, Garret Fitzgerald, Luis Garza. Compositions and methods for regulating hair growth. US Patent application 2015/0072963
- Pipeline KYTH-105 (setipiprant)
- http://files.shareholder.com/downloads/AMDA-MFNLA/4023632629x0x817836/4E5AC47A-B9EE-4296-9D97-631C0F6B7C97/KYTH-105_setipiprant_.pdf
| Patent ID | Date | Patent Title |
|---|---|---|
| US2015072963 | 2015-03-12 | COMPOSITIONS AND METHODS FOR REGULATING HAIR GROWTH |
| US2014328861 | 2014-11-06 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
| US2010234396 | 2010-09-16 | Tetrhydropyridoindole Derivatives |
| US7714132 | 2010-05-11 | Tetrahydropyridoindole derivatives |
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid
|
|
| Clinical data | |
| Administration | Oral |
| Identifiers | |
| CASRN | 866460-33-5 |
| ATC code | none |
| PubChem | CID 49843471 |
| Chemical data | |
| Formula | C24H19FN2O3 |
| Molar mass | 402.417 g/mol |
c15ccccc5cccc1C(=O)N(CC3)Cc2c3n(CC(O)=O)c(cc4)c2cc4F
/////////
20 Scrumptious Burmese Foods: Take a Bite of Burma (Myanmar)!
By Mark Wiens I was full the entire time I was in Yangon, Burma (Myanmar), and though I attempted, unfortunately I wasn’t able to eat everything the city had to offer. Just like the Bangkok street food, Yangon is yet another example of a SE Asian city where food is a top priority and street food is out of control!
1. Mohinga
At the forefront of Burmese cuisine is the famous dish of mohinga, a bowl of rice noodles covered in a fish based soup and sprinkled with deep fried fritters. Mohinga is a breakfast of champions!
2. Burmese Biryani
When I caught a glimpse of a restaurant called “Ambrosia Biryani,” there was absolutely no way I was going to get myself to walk past without sampling. Unfortunately the the biryani was a bit cold, having the appearance of yesterday’s ambrosia, but it was still tasty!
3. Burmese Naan Flat-bread and Pe Byouk
The bread is a form of Burmese Indian style
naan, pulled straight out of a clay pot cooking device. Pe Byouk is
what I believe to be a form of boiled peas. The vendor normally bagged
the beans and added a torn up naan on top – to go. Since I ate on spot, I
requested the burrito version of this hearty protein rich morning
snack.
4. Rice and Burmese Curry
Rice and a few accompanying curries and vegetables is a common meal of Burmese cuisine. The curries are mildly flavored, but they are pleasing and go extremely well with a plate (or 5) of rice.
5. Beans, Onions, Pumpkin
Beans, onions, and tomatoes dressed in oil and salt (left), mild pumpkin curry (right)
6. Burmese Fish Curry
A greasy, but unbelievable curry medley of fish.
7. Garnish Salads
Vegetables with a fermented fish sauce (left) and chili flake sauce (right).
8. Form of Khaosay Thote
A form of noodles hand mixed with a flavorful chili sauce and eaten with cloves of garlic and chilies (left), Fresh Burmese spring rolls (right)
9. Deep Fried Stuffed Tofu
Deep fried and stuffed with some cabbage, chilies and a special sauce made this tofu roll a single bite wonder!
10. Sticky Rice With Shredded Coconut
I’ll admit, I was extremely excited my first day in Yangon, Burma, and I had no idea what I was ordering. I saw some sticky rice and jumped at the opportunity to order it. This is what I got, and though I had no idea what I was supposed to mix and match, just like everything else it was delicious.
11. Selection of Mouthwatering Burmese Salads
(Clockwise from top-left corner)- Laphet Thohk – pickled tea leaf salad
- Lemon Salad – entirely made from red onions and lemon pulp
- Gyin Thohk – pickled ginger mixed salad
- Tofu Thohk – Tofu salad
- Another Lemon Pulp Salad
- Tomato and Cabbage Salad
12. Laphet Thohk – Green Tea Salad
It’s a famed dish, a salad made from pickled tea leaves. Apparently Burma is one of only a few countries in the world that drinks and eats tea leaves. The texture of the salad was unique, a adoring combination of soft, crunchy, crispy, and saucy. I could eat this salad constantly for days.
13. Burmese Indian Thali Mixed Platter
There’s not a lot in this world that is as enticing to me as an all-you-can eat meal. Thali is an Indian mixed dish cuisine that is served on a metal platter. Rice is scooped out of buckets and the food party doesn’t stop until the customer is fully satisfied!
14. Goat Testicles
Along with a Thali, there’s an opportunity to order a number of accompanying curries and sides. We got a duo-pari of goat testicles, and though the flavor was quite appetizing, their mushiness was reminiscent of chunks of pure lard.
15. Burmese Indian Dosa
I’ve been a huge fan of dosas for many years of my life, so when I scoped this street side dosa stand, there was no hesitation. The dosa was made on an iron skillet over fiery flames emitted by the burning of dry wood. The curry was smooth and the pancake did an excellent job of sopping up everything till the final drip.
16. Grilled Fish in Chinatown, Yangon
This grilled fish left me speechless, stunned, and overjoyed. It was so lip-licking delicious that I dreamed about it at night and my body was willingly forced to dine here 3 nights in a row!
17. Vegetables in Chinatown
Skewers of grilled garlic and okra (left) a plate of stir fried pumpkin leaves (right)
18. Mala Hin
Glorious vegetables in a spicy bean paste
19. Stuffed Pork Skewer
Marinated pork stuffed with straw mushrooms and green peppers
20. Burmese Falooda
The Burmese version of the falooda is sweet and stunning (similar to the Indian version)!
I’m nowhere near a Burmese food expert, but I can safely say that I enjoyed everything I ate in Yangon!
No comments:
Post a Comment